On the birth of breast cancer

被引:38
作者
Polyak, K
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2001年 / 1552卷 / 01期
关键词
breast cancer; tumor progression; DCIS (ductal carcinoma in situ); pre-invasive lesions;
D O I
10.1016/S0304-419X(01)00029-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast carcinoma is one of the most common neoplasms in women and is a leading cause of cancer related deaths worldwide. In recent years improved diagnostic tools have made it possible to detect breast cancers at early, even pre-invasive stages leading to a significant decrease in breast cancer mortality rates over the past decades. The increased number of patients diagnosed with pre-invasive breast tumors opened up new avenues in research and new dilemmas in clinical practice, since our understanding of the pathophysiology of such lesions is just beginning to emerge. Part of the delay and difficulty with analyzing pre-invasive tumors including ductal carcinoma in situ has been due to the lack of appropriate techniques suitable for studies of small, frequently microscopic size tumors. Recently developed technologies such as DNA microarrays and SAGE (serial analysis of gene expression) have made it possible to obtain comprehensive gene expression profiles of breast carcinomas of all stages. The application of these genomics approaches in combination with the complete sequence of the human genome and extensive molecular epidemiological studies is likely to further our understanding of the molecular basis of mammary tumorigenesis and will identify targets for risk prediction, cancer prevention and treatment. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 115 条
[31]  
Evron E, 2001, CANCER RES, V61, P2782
[32]   High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer [J].
Ferguson, AT ;
Evron, E ;
Umbricht, CB ;
Pandita, TK ;
Chan, TA ;
Hermeking, H ;
Marks, JR ;
Lambers, AR ;
Futreal, PA ;
Stampfer, MR ;
Sukumar, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (11) :6049-6054
[33]   Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
Wickerham, DL ;
Fisher, ER ;
Mamounas, E ;
Smith, R ;
Begovic, M ;
Dimitrov, NV ;
Margolese, RG ;
Kardinal, CG ;
Kavanah, MT ;
Fehrenbacher, L ;
Oishi, RH .
LANCET, 1999, 353 (9169) :1993-2000
[34]  
Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO
[35]  
2-Y
[36]   CLONAL 6P21 REARRANGEMENT IS RESTRICTED TO THE MESENCHYMAL COMPONENT OF AN ENDOMETRIAL POLYP [J].
FLETCHER, JA ;
PINKUS, JL ;
LAGE, JM ;
MORTON, CC ;
PINKUS, GS .
GENES CHROMOSOMES & CANCER, 1992, 5 (03) :260-263
[37]   Inactivation of p16 in human mammary epithelial cells by CpG island methylation [J].
Foster, SA ;
Wong, DJ ;
Barrett, MT ;
Galloway, DA .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (04) :1793-1801
[38]   BRCA1 MUTATIONS IN PRIMARY BREAST AND OVARIAN CARCINOMAS [J].
FUTREAL, PA ;
LIU, QY ;
SHATTUCKEIDENS, D ;
COCHRAN, C ;
HARSHMAN, K ;
TAVTIGIAN, S ;
BENNETT, LM ;
HAUGENSTRANO, A ;
SWENSEN, J ;
MIKI, Y ;
EDDINGTON, K ;
MCCLURE, M ;
FRYE, C ;
WEAVERFELDHAUS, J ;
DING, W ;
GHOLAMI, Z ;
SODERKVIST, P ;
TERRY, L ;
JHANWAR, S ;
BERCHUCK, A ;
IGLEHART, JD ;
MARKS, J ;
BALLINGER, DG ;
BARRETT, JC ;
SKOLNICK, MH ;
KAMB, A ;
WISEMAN, R .
SCIENCE, 1994, 266 (5182) :120-122
[39]  
Gouon-Evans V, 2000, DEVELOPMENT, V127, P2269
[40]   4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland [J].
Green, A ;
Shilkaitis, A ;
Christov, K .
CARCINOGENESIS, 1999, 20 (08) :1535-1540